NCT06016634 Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
| NCT ID | NCT06016634 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University of California, Davis |
| Condition | Sickle Cell Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-03-09 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 30 participants in total. It began in 2026-03-09 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis
Eligibility Criteria
Inclusion Criteria: * Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography) * Ability to provide written informed consent * Ability to lay on a dual-energy X-ray absorptiometry (DXA) scanner * Negative urine pregnancy test for anyone of childbearing potential at study entry Exclusion Criteria: * Pregnant women * Adults unable to consent * Individuals who are not yet adults (infants, children, teenagers) * Prisoners * Hospitalizations (for any cause) within 2 weeks of study entry
Contact & Investigator
Oyebimpe O Adesina, MD, MS
PRINCIPAL INVESTIGATOR
UC Davis School of Medicine
Frequently Asked Questions
Who can join the NCT06016634 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Sickle Cell Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06016634 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06016634 currently recruiting?
Yes, NCT06016634 is actively recruiting participants. Contact the research team at lyteos@health.ucdavis.edu for enrollment information.
Where is the NCT06016634 trial being conducted?
This trial is being conducted at Sacramento, United States.
Who is sponsoring the NCT06016634 clinical trial?
NCT06016634 is sponsored by University of California, Davis. The principal investigator is Oyebimpe O Adesina, MD, MS at UC Davis School of Medicine. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.